Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s stock price crossed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $3.92 and traded as high as $4.25. Ironwood Pharmaceuticals shares last traded at $4.13, with a volume of 1,319,660 shares traded.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Wall Street Zen downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 5th. Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Weiss Ratings lowered shares of Ironwood Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, September 4th. Finally, Jefferies Financial Group upgraded shares of Ironwood Pharmaceuticals to a “hold” rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $6.23.

Ironwood Pharmaceuticals Trading Down 1.4%

The company has a market cap of $682.44 million, a P/E ratio of 5.36 and a beta of 0.20. The firm’s 50 day moving average price is $4.16 and its 200-day moving average price is $3.92.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.31 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%.The business had revenue of $113.04 million for the quarter, compared to the consensus estimate of $114.84 million. Analysts predict that Ironwood Pharmaceuticals, Inc. will post 1.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, insider Ronald Silver sold 127,890 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total transaction of $578,062.80. Following the completion of the sale, the insider owned 313,680 shares in the company, valued at approximately $1,417,833.60. The trade was a 28.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 9.30% of the company’s stock.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Krilogy Financial LLC increased its holdings in Ironwood Pharmaceuticals by 9.8% in the first quarter. Krilogy Financial LLC now owns 33,194 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 2,971 shares during the last quarter. ProShare Advisors LLC boosted its holdings in Ironwood Pharmaceuticals by 9.6% during the fourth quarter. ProShare Advisors LLC now owns 36,315 shares of the biotechnology company’s stock worth $122,000 after buying an additional 3,170 shares during the last quarter. DGS Capital Management LLC boosted its holdings in Ironwood Pharmaceuticals by 42.8% during the first quarter. DGS Capital Management LLC now owns 14,883 shares of the biotechnology company’s stock worth $52,000 after buying an additional 4,458 shares during the last quarter. Hsbc Holdings PLC grew its position in shares of Ironwood Pharmaceuticals by 26.8% during the 1st quarter. Hsbc Holdings PLC now owns 29,706 shares of the biotechnology company’s stock worth $104,000 after buying an additional 6,270 shares during the period. Finally, EverSource Wealth Advisors LLC grew its position in shares of Ironwood Pharmaceuticals by 48.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 20,336 shares of the biotechnology company’s stock worth $71,000 after buying an additional 6,656 shares during the period.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused pharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines for gastrointestinal diseases and other disorders where significant unmet medical needs remain.

Ironwood’s primary marketed product is LINZESS (linaclotide), an oral medication used to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The product was approved by the U.S.